Sylvant
(Siltuximab)Phase 3Monoclonal antibody
Siltuximab is used to treat a rare blood cancer called multicentric Castleman disease, which causes swollen lymph nodes and inflammation throughout the body.[1] Sylvant is currently being investigated across 9 indications[3], with its most advanced program in Phase 3.[1]
Sylvant is one of 179 small molecule programs targeting Idiopathic Multicentric Castleman Disease. It is currently in Phase 3.
9
Indications
33
Total Trials
10
Active Trials
178
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
258 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Empliciti
Bristol-Myers SquibbPhase 3
Fludara
SanofiPhase 3
Keytruda
Merck & Co.Phase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Biaxin
AbbViePhase 3
Neulasta
AmgenPhase 3
Elranatamab
PfizerPhase 3
Cytosar
TevaPhase 3
Mozobil
GGenzyme, a Sanofi Company
Phase 3
Busulfex
Akero TherapeuticsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma8 trials
Show 5 more trials
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07106671·20 enrolled
Cytokine Release Syndrome2 trials
Prostate Cancer1 trial
Type 1 Diabetes1 trial
Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes
Completed·—·Phase 1·NCT02641522·10 enrolled
20 more indications
Myelodysplastic Syndrome1 trial
Essential Thrombocythemia1 trial
Treatment1 trial
Lymphoma1 trial
Efficacy and Safety1 trial
Monoclonal Gammopathy1 trial
Pneumonia1 trial
Chronic Lymphocytic Leukaemia1 trial
B-cell acute lymphoblastic leukemia1 trial
Ovarian Neoplasms1 trial
Advanced Malignant Solid Neoplasm1 trial
Antibody1 trial
Regulatory
FDA Approval Timeline[4]
Apr 23, 2014
SYLVANT
BLA BLA125496
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Siltuximab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Interleukin-6 Antagonist[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- RRECORDATI GROUP